Search

Azadirachta indica leaf

It is not an approved drug.

Alaproclate

Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.

RP01

It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … It could offer benefit to millions of asthma and allergy patients.

Lexibulin

CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

LErafAON

Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

Sodium phosphate, dibasic

Motixafortide

[L48141] It has also been investigated alongside [pembrolizumab] for the treatment of pancreatic cancer.[A261481] … [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple

Clopenthixol

It is an antagonist at D1 and D2 dopamine receptors.

Aloe ferox leaf

It is not an approved drug.

Eucalyptus globulus leaf

It is not an approved drug.